CDC25C and myelodysplastic syndrome: Depletion of CDC25C and PP2Acα with RNA interference resumes sensitivity to lenalidomide in non-del(5q) MDS/AML cells, indicating that haploinsufficiency of 5q genes confers therapeutic vulnerability to lenalidomide in del(5q) myeloid malignancies [33].